Health News Releases

February 22, 10:10

Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.

February 19, 10:59

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and

February 14, 08:55

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial. These ana

February 10, 11:00

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), a

February 09, 10:30

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial, which announces the US lau

February 08, 15:35

Avania Acquires MAXIS, Advancing MedTech Leadership in Pre-Clinical, Regulatory Strategy, and Clinical Expertise

Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of MAXIS, a prominent medical technology development service provider with expertise

February 08, 15:10

Parse Biosciences Announces Evercode TCR and Gene Capture

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand the Pa

February 08, 10:30

KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya

The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in

February 08, 10:00

IDC MarketScape Names Medidata a Leader in Life Science R&D Risk-Based Monitoring Solutions Vendor Assessment

Medidata, a Dassault Systèmes company, announced it has been positioned as a Leader in the IDC MarketScape “Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment (doc #US48

February 06, 10:20

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022). Takeda chief financial officer, Costa Saroukos, commented:

February 05, 11:20

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanade

February 05, 10:55

Dentalis Animal Health appoints Advisory Board

Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pha

February 05, 09:40

Dexlevo’s GOURI Symposium and Brand Event at IMCAS 2023

Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris. IMCAS (International

January 30, 17:30

Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares

EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular

January 27, 11:40

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifes

January 26, 16:26

Galderma Announces the Launch of FACE by Galderma™ - a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Grow Their Activity and Improve Patient Satisfaction

Galderma has announced the launch of FACE by Galderma™, an innovative augmented reality application. The ground-breaking solution enables aesthetic practitioners and patients to visualize treatment re

January 26, 10:40

Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed Gmb

January 25, 15:35

AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics ma

January 24, 11:15

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for

January 24, 10:13

Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery

Masimo (NASDAQ: MASI) today announced the findings of a prospective, single-blinded, randomized controlled study published in the Journal of Anesthesia & Intensive Care Medicine in which Dr. Mona Moha

January 21, 13:20

IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio

Galderma will be showcasing the latest updates from across its portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris from January 26-28, 2023. Events will

January 20, 14:10

Chief Rabbi of Israel Affirms Aleph Farms’ Cultivated Steak is Kosher

Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that Israeli Chief Rabbi, David Baruch Lau, has ruled its cultivate

January 20, 11:26

Kaneka expands GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A.

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: L

January 19, 14:30

TA Announces Strategic Growth Investment in Synokem Pharmaceuticals

TA Associates (“TA”), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (“Synokem” or “the Company”). Syn

January 19, 09:45

Agenda 2023: PQE Group Boosting Growth by Reinforcing Service Portfolio and Entering New Markets

It has been another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) with 32 offices worldwide. Recently named “Best Managed Company” by Deloitt

News by Region

News by Industry